Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

MSTX RSS Feed
Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator LaJollaCA, Rhodey Red
Search This Board:
Last Post: 8/16/2014 12:57:10 PM - Followers: 304 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.


http://wsw.com/webcast/cowen16/MSTX/  Webcast from Cowen Healthcare Conference 03/03/14

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_07.09.2013.pdf


http://www.media-server.com/m/p/to9vgb8uhttp://www.media-server.com/m/p/to9vgb8u  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_10.08.2013.pdf    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW

http://www.masttherapeutics.com/company/ceo-blog/ 
Blog Update from CEO B. Culley 12/12/13  NEW

http://www.masttherapeutics.com/investors/news/?releaseid=1887966  Data From Proof of Concept Study in Heart Failure 
01/06/13


ClinicalTrials.gov

 
A service of the U.S. National Institutes of Health

 

  • Make bi

 

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Sponsor:
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01737814
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.


Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
 
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
 
Further study details as provided by Mast Therapeutics, Inc.:
 
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
 
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline

 

 
Please refer to this study by its ClinicalTrials.gov identifier: NCT01737814

Contacts
Contact: Mast Therapeutics CT.gov Call Center 1-888-965-1238  

 
Responsible Party: Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 25, 2013

 

Technology

 

Hematology

MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


Oncology

Exelbine™

Exelbine™, or ANX-530 (vinorelbine injectable emulsion), is a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®). We are seeking a partner or outside investor to continue development of the Exelbine program.

ANX-514

ANX-514 (docetaxel for injectable emulsion) is a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel. We are seeking a partner or outside investor to continue development of the ANX-514 program.



2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing


Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

 

Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug 
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be 
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.pdf

http://whalewisdom.com/stock/mstx

http://whalewisdom.com/schedule13d/view/90323

http://whalewisdom.com/schedule13d/view/103504

http://whalewisdom.com/schedule13d/view/90288

http://whalewisdom.com/filer/stock_history/ancora-advisors-llc/mstx/
 

Schedule 13D and 13G filings submitted since 03/31/2013

  Filing Company Date of
Filing
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 03/31/14 3,000,000 3,000,000
SC 13G SABBY MANAGEMENT, LLC 01/14/2014 4,105,500 3,639,571
SC 13G FRANKLIN RESOURCES INC 07/10/2013 10,987,000 12,000,000
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F     MSTX      
13F     MSTX      
 



 

                                                                       






http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381

http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928

http://stockcharts.com/freecharts/gallery.html?MSTX

                                                       

Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries
info@mastthera.com

Investor Relations Contact
ir@mastthera.com

Business Development Contact
busdev@mastthera.com

Careers Contact
hr@mastthera.com

 

                                                                                                 

                                                                                                                                                 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSTX
Current Price
Volume:
Bid Ask Day's Range
Wiki
ANX News: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 06/16/2014 08:00:00 AM
ANX News: Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease 04/14/2014 08:00:00 AM
PostSubject
#12276   Your ridiculous thought processes that dwell on the Rhodey Red 08/16/14 10:22:55 AM
#12274   We do not know if Rhodey in any Cicant 08/16/14 03:03:05 AM
#12272   Indeed we will Cicant!!! All the way to Rhodey Red 08/15/14 08:38:18 PM
#12271   If the first 12-17 months the updates for Cicant 08/15/14 11:11:02 AM
#12270   Yesterday's corporate presentation was excellent. We received a Rhodey Red 08/15/14 09:10:46 AM
#12269  Restored Any thoughts on the presentation? Rhodney? The Sliver Man 08/15/14 12:47:17 AM
#12268   Mast have 4 catalist to end 2014 and sedrik 08/13/14 08:51:07 AM
#12267   Mast Therapeutics To Present At The Canaccord Genuity sedrik 08/13/14 08:49:56 AM
#12266   Up today tomorrow news from conference coming sedrik 08/13/14 08:49:46 AM
#12264   MSTX 4 catalist near 6 month coming sedrik 08/13/14 05:40:35 AM
#12263   Green today, tomorrow news coming from conference sedrik 08/13/14 05:38:37 AM
#12262   Surely this thing has to start moving at The Sliver Man 08/11/14 10:31:14 PM
#12261   Looks positive going forward. One near term TriggerPuller79 08/11/14 08:24:31 PM
#12260   Balance Sheet Highlights Cicant 08/11/14 08:53:07 AM
#12259   The week ahead should be interesting. Just a Rhodey Red 08/11/14 07:13:00 AM
#12258   Thank you very much RR! You as well$$$$ alphaInvestor2 08/08/14 01:50:11 PM
#12256   Alphainvestor2 reply part II: Rhodey Red 08/07/14 08:33:17 PM
#12255   Hey there alphainvestor2,here is a quick breakdown to Rhodey Red 08/07/14 05:34:38 PM
#12253   What phase if any are MSTX products in alphaInvestor2 08/07/14 10:11:54 AM
#12249   Once again you've missed the mark TSM. You Rhodey Red 08/07/14 08:54:28 AM
#12247   http://www.marketwatch.com/story/mast-therapeutics-to-present-at-the-canaccord-g Rhodey Red 08/07/14 08:07:01 AM
#12245  Restored ?????? What stuff?? The Sliver Man 08/06/14 08:44:19 PM
#12244   look at this i leave the board for okaly 08/06/14 05:23:49 PM
#12243   SAN FRANCISCO, CA--(Marketwired - Aug 5, 2014) - harmsen 08/05/14 09:08:34 AM
#12242   "Clutching at straws???? What is wrong with you??? Rhodey Red 08/03/14 04:59:08 PM
#12241   Absolutely Trigger. Again, we could just be handed Rhodey Red 08/03/14 04:44:07 PM
#12240   I am also looking forward to seeing how TriggerPuller79 08/03/14 03:25:38 PM
#12238   Looking forward to our Q2 earnings release that Rhodey Red 08/02/14 10:17:13 PM
#12237   Scleroderma is a systemic autoimmune disease where the Rhodey Red 07/30/14 06:46:41 PM
#12236   Good sized Block on the bid side just Lucyndahouse 07/30/14 01:09:59 PM
#12235   Can you explain "scleroderma" in layman terms? RNsidersbuying 07/30/14 09:27:17 AM
#12234   The combination of company driven catalysts over the Rhodey Red 07/29/14 04:59:50 PM
#12233   Sounds like a reasonable plan to me. I The Sliver Man 07/29/14 11:23:25 AM
#12232   I don't have a specific $$$ in mind Rhodey Red 07/29/14 11:02:31 AM
#12231   May I ask, what price are you hoping The Sliver Man 07/29/14 08:46:31 AM
#12230   Added another 12,000 shares at .585 on the open. Rhodey Red 07/28/14 10:04:55 AM
#12229   I agree and want to do that. Even The Sliver Man 07/27/14 12:51:13 AM
#12228   Past pr's pointed to the fall of 2014 pray 07/27/14 12:16:37 AM
#12227   Here is the article. http://sclerodermainfo.org/?attachment_id=524 Rhodey Red 07/26/14 11:37:48 PM
#12226   Interesting message thread.https://www.inspire.com/groups/scleroderma-foundation Rhodey Red 07/26/14 11:35:47 PM
#12225   The highest I bought in was at $3 The Sliver Man 07/26/14 11:17:16 PM
#12224   Although I also disagree with a lot of pray 07/26/14 12:06:45 PM
#12223   For all newcomers, Silver Man is pretty much Gravitate_Z 07/25/14 05:05:54 PM
#12222   Funny guy tell that to the baker brothers. akamaii 07/25/14 12:17:33 PM
#12221   So has everyone now given up on this now? The Sliver Man 07/25/14 12:30:59 AM
#12220   No just bought almost 40k shares Dara. Stay akamaii 07/23/14 10:40:54 AM
#12219   Don't you ever get bored? The Sliver Man 07/23/14 10:39:14 AM
#12218   Target today 62 and officially new uptrend as akamaii 07/23/14 09:15:16 AM
#12217   Well, I know one that has a cancer akamaii 07/22/14 11:52:59 AM
#12216   Yeah, nice! I like this one for a akamaii 07/22/14 11:49:22 AM
PostSubject